Clinical Trial Update: A Study to Examine the Effect of Reconval K1 Cream to Prevent Skin Toxicity From EGFRI [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Reconval K1 Cream to prevent skin toxicity from EGFR inhibitors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rash Due to Epidermal Growth Factor Receptor Inhibitors

Drugs mentioned

• Reconval K1 Cream

Snippet

Sponsor: Hadassah Medical Organization | Conditions: Rash Due to Epidermal Growth Factor Receptor Inhibitors | Phase 2 | Status: COMPLETED